Ceregene - Newsroom

Press Releases

08.05.09	Ceregene Receives Additional Grant from Michael J. Fox Foundation to Expand Long-Term Testing of CERE-120 Patients
05.27.09	Ceregene Presents Additional Clinical Data from Phase 2 Trial of CERE-120 for Parkinson's Disease
11.26.08	Ceregene Announces Clinical Data from Phase 2 Clinical Trial of CERE-120 for Parkinson's Disease
11.04.08	Ceregene Phase 2 Clinical Trial for Alzheimer's Disease to be Funded by $5.4 Million Grant from National Institutes of Health
04.23.08	Ceregene Announces Two Key Additions to Leadership Team
01.07.08	Ceregene to Present at JPMorgan 26th Annual Healthcare Conference
12.12.07	Ceregene Presents Long-Term Follow-Up from Phase 1 Trial of CERE-120 in Parkinson's Disease
12.06.07	Ceregene Promotes Dr. Raymond Bartus to Executive Vice President
11.14.07	Ceregene Completes Enrollment of Phase 2 Clinical Trial for Parkinson's Disease
06.21.07	Ceregene and Genzyme Announce Partnership for the Development and Commercialization of CERE-120 for Parkinson's Disease
05.02.07	Ceregene Presents Interim Phase I Clinical Data of CERE-110 for the Treatment of Alzheimer's Disease
04.16.07	Ceregene Presents Long Term Follow-Up Data from Phase I Trial of CERE-120 Demonstrating Improved Motor Function in Parkinson's Patients
04.13.07	Growth Factor Therapy Appears to Improve Symptoms in Mid-Stage Parkinson's Disease